ES2304264A1 - Terapia de combinacion para tratar enfermedades. - Google Patents

Terapia de combinacion para tratar enfermedades. Download PDF

Info

Publication number: ES2304264A1
Authority: ES; Spain
Prior art keywords: antigen; antibody; alt; patient; precedents
Prior art date: 2001-10-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

ES200450028A

Other languages

English (en)

Spanish (es)

Inventor

Birgit Schultes

Christopher F. Nicodemus

Antoine Noujaim

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Altarex Medical Corp

Original Assignee

Altarex Medical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-26

Filing date

2002-10-28

Publication date

2008-10-01

2002-10-28 Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp

2008-10-01 Publication of ES2304264A1 publication Critical patent/ES2304264A1/es

Status Pending legal-status Critical Current

Links

201000010099 disease Diseases 0.000 title description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 11
238000002648 combination therapy Methods 0.000 title description 2
239000000427 antigen Substances 0.000 claims abstract description 51
102000036639 antigens Human genes 0.000 claims abstract description 51
108091007433 antigens Proteins 0.000 claims abstract description 51
206010028980 Neoplasm Diseases 0.000 claims abstract description 48
201000011510 cancer Diseases 0.000 claims abstract description 34
239000002246 antineoplastic agent Substances 0.000 claims abstract description 23
229940044683 chemotherapy drug Drugs 0.000 claims abstract description 22
238000001727 in vivo Methods 0.000 claims abstract description 7
230000028993 immune response Effects 0.000 claims description 17
241001529936 Murinae Species 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 9
238000001356 surgical procedure Methods 0.000 claims description 8
230000000973 chemotherapeutic effect Effects 0.000 claims description 7
238000001802 infusion Methods 0.000 claims description 6
238000001990 intravenous administration Methods 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 2
238000002483 medication Methods 0.000 claims 1
229940125645 monoclonal antibody drug Drugs 0.000 claims 1
239000011230 binding agent Substances 0.000 abstract description 22
238000000034 method Methods 0.000 abstract description 20
239000000203 mixture Substances 0.000 abstract description 10
230000005745 host immune response Effects 0.000 abstract description 8
230000001939 inductive effect Effects 0.000 abstract description 5
210000002966 serum Anatomy 0.000 abstract description 2
238000002512 chemotherapy Methods 0.000 description 18
238000011282 treatment Methods 0.000 description 16
210000004027 cell Anatomy 0.000 description 15
210000001744 T-lymphocyte Anatomy 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
231100000135 cytotoxicity Toxicity 0.000 description 6
230000003013 cytotoxicity Effects 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 4
101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 4
102100023123 Mucin-16 Human genes 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
108010074328 Interferon-gamma Proteins 0.000 description 3
102100034256 Mucin-1 Human genes 0.000 description 3
108010008707 Mucin-1 Proteins 0.000 description 3
102000008300 Mutant Proteins Human genes 0.000 description 3
108010021466 Mutant Proteins Proteins 0.000 description 3
102000007066 Prostate-Specific Antigen Human genes 0.000 description 3
108010072866 Prostate-Specific Antigen Proteins 0.000 description 3
230000005867 T cell response Effects 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000004913 activation Effects 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
101710113436 GTPase KRas Proteins 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
102100037850 Interferon gamma Human genes 0.000 description 2
208000030961 allergic reaction Diseases 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
230000004044 response Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
201000004384 Alopecia Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
190000008236 carboplatin Chemical compound 0.000 description 1
230000007681 cardiovascular toxicity Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
229960000520 diphenhydramine Drugs 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
229940035756 doxorubicin injection Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000008693 nausea Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
229950007283 oregovomab Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000003439 radiotherapeutic effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
101150047061 tag-72 gene Proteins 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
229960002190 topotecan hydrochloride Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Pregnancy & Childbirth (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gynecology & Obstetrics (AREA)
Genetics & Genomics (AREA)
Reproductive Health (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ES200450028A 2001-10-26 2002-10-28 Terapia de combinacion para tratar enfermedades. Pending ES2304264A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33924001P	2001-10-26	2001-10-26
US60/339,240		2001-10-26

Publications (1)

Publication Number	Publication Date
ES2304264A1 true ES2304264A1 (es)	2008-10-01

Family

ID=23328122

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES200450028A Pending ES2304264A1 (es)	2001-10-26	2002-10-28	Terapia de combinacion para tratar enfermedades.

Country Status (9)

Country	Link
AT (1)	AT500649A1 (fr)
AU (1)	AU2002358246B2 (fr)
CA (1)	CA2464947C (fr)
CH (1)	CH696871A5 (fr)
DE (1)	DE10297379T5 (fr)
ES (1)	ES2304264A1 (fr)
GB (1)	GB2397018B (fr)
NO (1)	NO20042166L (fr)
WO (1)	WO2003034977A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8038994B2 (en)	1996-05-15	2011-10-18	Quest Pharmatech Inc.	Combination therapy for treating disease
WO2008091643A2 (fr) *	2007-01-23	2008-07-31	Altarex Medical Corp.	Système de culture in vitro pour évaluer la synergie du ciblage de voies immunosuppressives concomitantes à une immunothérapie

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994027637A1 (fr) *	1993-05-27	1994-12-08	Uwe Wagner	Anticorps monoclonaux anti-ca125 et antiidiotypiques, et compositions pharmaceutiques les contenant
WO1997042973A1 (fr) *	1996-05-15	1997-11-20	Altarex, Corp.	Methode et composition permettant de modifier la configuration des antigenes a epitopes multiples pour provoquer une reponse immunitaire
WO2001012217A1 (fr) *	1999-08-18	2001-02-22	Altarex Corp.	Anticorps therapeutiques utilises contre l'antigene muc-1, et leurs procedes d'utilisation
WO2001015730A1 (fr) *	1999-08-27	2001-03-08	Genentech, Inc.	DOSAGES POUR TRAITEMENT AVEC DES ANTICORPS ANTI-ErbB2
WO2002076384A2 (fr) *	2001-03-21	2002-10-03	Altarex Corp.	Compositions therapeutiques permettant de modifier la reponse immunitaire

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GEP20104998B (en) *	1999-06-25	2010-06-10	Genentech Inc	Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
DE69934259T2 (de) *	1999-07-23	2007-05-31	Glaxo Group Ltd., Greenford	Kombination von einem Anti-Ep-CAM-Antikörper mit einem chemotherapeutischen Mittel
DK1254374T3 (da) *	2000-02-08	2007-09-03	Altarex Medical Corp	Fremgangsmåde til diagnose af effektiviteten ved xenotype-antistofbehandling

2002
- 2002-10-28 CH CH00729/04A patent/CH696871A5/de not_active IP Right Cessation
- 2002-10-28 AT AT0923902A patent/AT500649A1/de not_active Application Discontinuation
- 2002-10-28 ES ES200450028A patent/ES2304264A1/es active Pending
- 2002-10-28 DE DE10297379T patent/DE10297379T5/de not_active Withdrawn
- 2002-10-28 CA CA2464947A patent/CA2464947C/fr not_active Expired - Lifetime
- 2002-10-28 WO PCT/IB2002/005794 patent/WO2003034977A2/fr not_active Ceased
- 2002-10-28 AU AU2002358246A patent/AU2002358246B2/en not_active Ceased
- 2002-10-28 GB GB0409191A patent/GB2397018B/en not_active Expired - Fee Related
2004
- 2004-05-25 NO NO20042166A patent/NO20042166L/no not_active Application Discontinuation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994027637A1 (fr) *	1993-05-27	1994-12-08	Uwe Wagner	Anticorps monoclonaux anti-ca125 et antiidiotypiques, et compositions pharmaceutiques les contenant
WO1997042973A1 (fr) *	1996-05-15	1997-11-20	Altarex, Corp.	Methode et composition permettant de modifier la configuration des antigenes a epitopes multiples pour provoquer une reponse immunitaire
WO2001012217A1 (fr) *	1999-08-18	2001-02-22	Altarex Corp.	Anticorps therapeutiques utilises contre l'antigene muc-1, et leurs procedes d'utilisation
WO2001015730A1 (fr) *	1999-08-27	2001-03-08	Genentech, Inc.	DOSAGES POUR TRAITEMENT AVEC DES ANTICORPS ANTI-ErbB2
WO2002076384A2 (fr) *	2001-03-21	2002-10-03	Altarex Corp.	Compositions therapeutiques permettant de modifier la reponse immunitaire

Also Published As

Publication number	Publication date
AU2002358246B2 (en)	2008-02-28
CA2464947C (fr)	2012-05-22
GB2397018B (en)	2006-05-31
WO2003034977A2 (fr)	2003-05-01
DE10297379T5 (de)	2004-10-14
CH696871A5 (de)	2008-01-15
WO2003034977A3 (fr)	2004-05-27
NO20042166L (no)	2004-05-25
GB0409191D0 (en)	2004-05-26
CA2464947A1 (fr)	2003-05-01
AT500649A1 (de)	2006-02-15
GB2397018A (en)	2004-07-14

Publication	Publication Date	Title
KR102470294B1 (ko)	2022-11-28	암을 치료하기 위한 항-pd1 항체 및 방사선의 조합
ES2768990T3 (es)	2020-06-24	Combinación de anticuerpos anti-CTLA4 con gemcitabina para el tratamiento sinérgico de enfermedades proliferativas
ES2563439T5 (es)	2022-02-04	Medios y métodos para tratar LDCBG
Acheampong et al.	2018	Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy
CN111132696B (zh)	2023-05-16	Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
JP2017503014A (ja)	2017-01-26	がんの治療のための組合せ調製物
CN105050625A (zh)	2015-11-11	通过抗-cd3免疫毒素的免疫调节治疗没有均一地含有表面cd3的癌症
ES2454990T3 (es)	2014-04-14	Quimioterapia e inmunoterapia simultáneas
CN114423453A (zh)	2022-04-29	使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit)
TW202330040A (zh)	2023-08-01	抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
JP6077641B2 (ja)	2017-02-08	新規ｃｔｌエピトープ５連結ペプチド
US20100008980A1 (en)	2010-01-14	Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with Surgery, Chemotherapy or Radiotherapy for the Treatment of Cancer
ES2304264A1 (es)	2008-10-01	Terapia de combinacion para tratar enfermedades.
DK3028048T3 (en)	2019-01-21	COMPOSITIONS FOR TREATMENT AND PREVENTION OF CANCER TARGETING AGAINST TUMOR-ASSOCIATED CARBOHYDRATE ANTIGEN
ES2966116T3 (es)	2024-04-18	Composiciones para modular la transducción de señales PD-1
AU2002358246A1 (en)	2003-07-03	Combination therapy for treating disease
Pandey et al.	1999	Cancer vaccines: a step towards prevention and treatment of cancer
Chaturvedi et al.	2026	Immunotherapy for breast cancer
JPWO2019246595A5 (fr)	2022-09-12
HELLSTRÖM et al.	1988	Therapeutic Use of Antimelanoma Monoclonal Antibodies
HK1188137A (en)	2014-04-25	Concurrent chemotherapy and immunotherapy
HK1223155B (en)	2019-10-04	Compositions for treating and preventing cancer targeting tumor associated carbohydrate antigens
HK1136486A (en)	2010-07-02	Concurrent chemotherapy and immunotherapy

Legal Events

Date	Code	Title	Description
2008-10-01	EC2A	Search report published	Date of ref document: 20081001 Kind code of ref document: A1
2010-04-19	FC2A	Grant refused	Effective date: 20100329

Date

Code

Title

Description

2008-10-01

EC2A

Search report published

Date of ref document: 20081001

Kind code of ref document: A1

2010-04-19

FC2A

Grant refused

Effective date: 20100329